Tempus AI (NASDAQ:TEM – Get Free Report) and Enovis (NYSE:ENOV – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.
Institutional & Insider Ownership
24.2% of Tempus AI shares are held by institutional investors. Comparatively, 98.4% of Enovis shares are held by institutional investors. 26.3% of Tempus AI shares are held by company insiders. Comparatively, 2.7% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Tempus AI and Enovis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tempus AI | -19.27% | -53.30% | -11.28% |
| Enovis | -52.69% | 8.74% | 4.19% |
Risk and Volatility
Analyst Ratings
This is a summary of recent ratings and target prices for Tempus AI and Enovis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tempus AI | 2 | 3 | 9 | 0 | 2.50 |
| Enovis | 1 | 0 | 6 | 2 | 3.00 |
Tempus AI presently has a consensus price target of $71.36, indicating a potential upside of 44.01%. Enovis has a consensus price target of $47.43, indicating a potential upside of 88.96%. Given Enovis’ stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than Tempus AI.
Earnings and Valuation
This table compares Tempus AI and Enovis”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tempus AI | $1.27 billion | 6.97 | -$245.03 million | ($1.41) | -35.14 |
| Enovis | $2.25 billion | 0.64 | -$1.18 billion | ($20.71) | -1.21 |
Tempus AI has higher earnings, but lower revenue than Enovis. Tempus AI is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.
Summary
Enovis beats Tempus AI on 8 of the 15 factors compared between the two stocks.
About Tempus AI
Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
